Michael Morin
Chairman at NCI Experimental Therapeutics Program
Profile
Michael J.
Morin is currently the Chairman of the Drug Discovery Initiative at the Children's Tumor Foundation and Co-Chairman at the NCI Experimental Therapeutics Program.
He previously worked as the Chief Executive Officer at Supportive Therapeutics, Vice President of Global Research & Development at Pfizer Inc., Chief Scientific Officer at Immunome, Inc., and Chief Scientific Officer at Onkaido Therapeutics LLC.
Morin holds a doctorate degree from the State University of New York at Buffalo and an undergraduate degree from the University of Lowell.
Michael Morin active positions
Companies | Position | Start |
---|---|---|
NCI Experimental Therapeutics Program | Chairman | - |
Children's Tumor Foundation | Corporate Officer/Principal | - |
Former positions of Michael Morin
Companies | Position | End |
---|---|---|
Onkaido Therapeutics LLC
Onkaido Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Moderna, Inc., Onkaido Therapeutics LLC offers advancement of oncology products for previously undruggable targets and as a superior alternative to existing drug modalities. The company is based in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 31/08/2015 |
Supportive Therapeutics | Chief Executive Officer | 30/11/2014 |
PFIZER, INC. | Chief Tech/Sci/R&D Officer | - |
IMMUNOME, INC. | Chief Executive Officer | 30/04/2019 |
Training of Michael Morin
State University of New York at Buffalo | Doctorate Degree |
University of Lowell | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PFIZER, INC. | Health Technology |
IMMUNOME, INC. | Health Technology |
Private companies | 4 |
---|---|
Children's Tumor Foundation | Miscellaneous |
Supportive Therapeutics | |
Onkaido Therapeutics LLC
Onkaido Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Moderna, Inc., Onkaido Therapeutics LLC offers advancement of oncology products for previously undruggable targets and as a superior alternative to existing drug modalities. The company is based in Cambridge, MA. | Health Technology |
NCI Experimental Therapeutics Program |
- Stock Market
- Insiders
- Michael Morin